| Literature DB >> 30961282 |
Jeremy B Vines1, Dong-Jin Lim2, Hansoo Park3.
Abstract
Current approaches for the treatment of cancer, such as chemotherapy, radiotherapy, immunotherapy, and surgery, are limited by various factors, such as inadvertent necrosis of healthy cells, immunological destruction, or secondary cancer development. Hyperthermic therapy is a promising strategy intended to mitigate many of the shortcomings associated with traditional therapeutic approaches. However, to utilize this approach effectively, it must be targeted to specific tumor sites to prevent adverse side effects. In this regard, photothermal therapy, using intravenously-administered nanoparticle materials capable of eliciting hyperthermic effects in combination with the precise application of light in the near-infrared spectrum, has shown promise. Many different materials have been proposed, including various inorganic materials such as Au, Ag, and Germanium, and C-based materials. Unfortunately, these materials are limited by concerns about accumulation and potential cytotoxicity. Polymer-based nanoparticle systems have been investigated to overcome limitations associated with traditional inorganic nanoparticle systems. Some of the materials that have been investigated for this purpose include polypyrrole, poly-(3,4-ethylenedioxythiophene):poly(4-styrenesulfonate) (PEDOT:PSS), polydopamine, and polyaniline. The purpose of this review is to summarize these contemporary polymer-based nanoparticle technologies to acquire an understanding of their current applications and explore the potential for future improvements.Entities:
Keywords: photothermal therapy; polyaniline; polydopamine; polymeric nanoparticle; polypyrrole
Year: 2018 PMID: 30961282 PMCID: PMC6401975 DOI: 10.3390/polym10121357
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Summary of Polymer Based Nanoparticle Systems for Photothermal Therapy.
| Polymer | Configuration | Testing Stage | Reference |
|---|---|---|---|
| Polyaniline | Nanoparticle | In-Vitro | [ |
| F-127 Conjugated Nanoparticle | In-Vitro and In-Vivo | [ | |
| Silver nanoparticle core, polyaniline shell (ICG-Ag@PANI) | In-Vitro and In-Vivo | [ | |
| Nanoparticles with lanreotide and methotrexate (LT-MTX/PANI NPs) | In-Vitro and In-Vivo | [ | |
| Nanoparticles with lipid layer and folic acid conjugation (FA-Lipid-PANI NPs) | In-Vitro and In-Vivo | [ | |
| WS core, polyaniline shell with hyaluronic acid and clorin e6 (Ce6) | In-Vitro and In-Vivo | [ | |
| polyaniline and cisplastin within folate-poly (ethylene glycol)-distearoylphosphatidylcholine (FA-PEG-DSPE), cRGD [cyclic (Arg-Gly-Asp-D-Phe-Lys)]-PEG-DSPE, and lecithin conjugates dubbed FA/cRGD-PNPs | In-Vitro and In-Vivo | [ | |
| Polypyrrole | Base Nanoparticles | In-Vitro and In-Vivo | [ |
| Base Nanoparticles | In-Vitro | [ | |
| Polypyrrole chains synthesized on mesoporous amno-functionalized dendrimer-like silica nanoparticles (DSNs-NH2) PPy@DSNs-NH2 loaded with doxorubicin | In-Vitro | [ | |
| Spindle-like hollow polypyrrole nanocapsules (PPy HNCs) loaded with doxorubicin | In-Vivo | [ | |
| Ppy and rapamycin loaded into liposomes conjugated with trastuzumab (LRPmAB) | In-Vitro | [ | |
| Polydopamine | Dopamine-melanin colloidal nanospheres | In-Vitro and In-Vivo | [ |
| PEGYlated polydopamine nanoparticles conjugatd with ICG (PDA-ICG-PEG) loaded with doxorubicin | In-Vitro | [ | |
| PEGylated nanoparticles loaded with 7-ethyl-10-hydroxycampthotheticin (SN38) | In-Vivo | [ | |
| Doxorubicin encapsulated within DSPE-PEG micelles coated with polydopamine | In-Vitro and In-Vivo | [ | |
| Fe(3)O(4) core polydopamine coated nanoshell | In-Vitro | [ | |
| polydopamine coated gold nanorods | In-Vitro | [ | |
| Polydopamine coated gold/silver nanoparticles | In-Vitro | [ | |
| PEDOT:PSS | PEGylated PEDOT:PSS nanoparticles (PDOT:PSS-PEG) | In-Vivo | [ |
| PEDOT:PSS-PEG loaded with doxorubicin, SN38, and Ce6 | In-Vitro | [ | |
| Magnetic nanoparticles with PEDOT:PSS, Cyanine7 (Cy7), and 2-deoxyglucose (2-DG)-polyethylene glcol (MNP@PES-Cy7/2-DG) | In-Vitro and In-Vivo | [ | |
| Magnetic nanoparticles with PEDOT:PSS coating | In-Vivo | [ | |
| TBDOPV-DT | D-A conjugated polymer (TBDOPV-DT), with 2,2-bithiophene serving as a donor and thiophene-fused benzodifurandione-based oligo(p-phenylenevinylene) as an acceptor (TBDOPV-DT NPs) | In-Vitro and In-Vivo | [ |
Figure 1An example of polyaniline-based nanoparticles for photothermal therapy. (A) Photothermal images of a mouse after intratumoral injection of F127-modified polyaniline nanoparticles (F-PANPs) (1 mg/mL) with an 808 nm laser (0.5 W cm−2, 3 min). When irradiated within the white circle area, the tumor (Point 1) and the surrounding tissue (Point 2) were heated. (B) Photothermal images of the tumor obtained at different time points. The scale bar indicates the temperature difference between 30 °C and 50 °C. (C) The relationship between sample temperature and laser illumination time is shown in (A). Reproduced from [24] with permission, copyright Elsevier, 2013.
Figure 2A polypyrrole-based nanocomposite for near-infrared (NIR) photothermal therapy. NIR thermographic images (a) and temperature change (b) in tumor-bearing mice after intratumoral injection of PBS and chitosan-polypyrrole nanocomposites (CS-PPy NCs) and irradiation with an 808 nm laser (2.0 W cm−2, 5 min). (c) The change in tumor size between Day 0 (before treatment) and 20 days after treatment. (d) Tumor volume growth curves for different groups of mice after different treatments. (e) The body weight after different treatments indicated over 20 days. The error bars indicate the mean ± standard deviation. Reproduced from [80] under open access license.
Figure 3The NIR-II photothermal approach by a novel nanoagent. In vivo photothermal therapy of tumors. Mice were subjected to whole-body IR images after injection with a narrow band gap D–A conjugated polymer (TBDOPV–DT), with 2,2-bithiophene as the donor and thiophene-fused benzodifurandione-based oligo(p-phenylenevinylene) as the acceptor. (a) Intratumoral (0.56 mg kg−1, 0.9 W cm−2, and a 1064 nm laser) or (b) intravenous (1.94 mg kg−1, 1.3 W cm−2) administration. (c) Growth rates of tumors after different treatments. (d) Representative size of the excised tumors. (e) Weight of tumor in each condition. (f) Changes in body weight of the mice with tumors. ** p ≤ 0.01; *** p ≤ 0.001. (g) H&E staining of tumor regions in different groups. Scale bars indicate 100 μm. Reproduced from [76] with permission, copyright American Chemical Society, 2018.